iRhythm Technologies Inc
$ 127.84
-0.22%
07 Aug - close price
- Market Cap 4,201,130,000 USD
- Current Price $ 127.84
- High / Low $ 136.69 / 123.56
- Stock P/E N/A
- Book Value 4.91
- EPS -0.42
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.10 %
- 52 Week High 212.00
- 52 Week Low 100.85
About
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Analyst Target Price
$177.07
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-04-30 | 2026-02-19 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-20 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 |
| Reported EPS | 0.58 | -0.35 | 0.17 | -0.06 | -0.32 | -0.95 | 0.01 | -1.26 | -0.61 | -1.23 | -1.26 | -0.79 |
| Estimated EPS | -0.01 | -0.64 | 0.01 | -0.28 | -0.47 | -0.94 | -0.28 | -0.57 | -0.88 | -0.99 | -0.6 | -0.58 |
| Surprise | 0.59 | 0.29 | 0.16 | 0.22 | 0.15 | -0.01 | 0.29 | -0.69 | 0.27 | -0.24 | -0.66 | -0.21 |
| Surprise Percentage | 5900% | 45.3125% | 1600% | 78.5714% | 31.9149% | -1.0638% | 103.5714% | -121.0526% | 30.6818% | -24.2424% | -110% | -36.2069% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRTC
2026-08-08 06:11:58
Wall Street Zen has downgraded iRhythm Technologies (NASDAQ:IRTC) to a "Hold" rating from "Buy," despite the company's strong Q2 results and a broader analyst consensus of "Moderate Buy." iRhythm reported earnings of $0.58 per share against an expected loss and saw revenue increase by 20.1% year-over-year. The company also announced the acquisition of VitalConnect for $287.5 million, expanding its cardiac-monitoring portfolio, and provided a positive 2026 revenue outlook.
2026-08-07 22:11:58
Needham has lowered its price target for iRhythm Technologies (NASDAQ: IRTC) to $192.00 from $255.00, while maintaining a Buy rating. This adjustment comes despite iRhythm exceeding second-quarter revenue expectations and raising its 2026 revenue guidance, as well as announcing the acquisition of VitalConnect which is expected to be accretive to growth and expand its market reach. The firm cited a lower target multiple as the reason for the reduced price target, noting that InvestingPro analysis suggests the stock may be overvalued despite its recent performance.
2026-08-07 21:11:58
This article provides current stock information for iRhythm Technologies Inc (IRTC), including its stock price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the TradingKey platform for investors.
2026-08-07 19:11:58
Truist Securities has increased its price target for iRhythm Technologies (IRTC) to $168 from $160, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance by the investment bank.
2026-08-07 13:10:57
Needham has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $192 from $255, while maintaining a Buy rating. The adjustment comes despite iRhythm exceeding Q2 2026 revenue expectations and raising its full-year guidance, partly due to the acquisition of VitalConnect which is expected to boost growth and maintain strong gross margins. Analysts anticipate profitability for iRhythm this year, although the firm's price target was reduced based on a lower target multiple.
2026-08-07 11:10:57
iRhythm Technologies, Inc. (IRTC) reported strong Q2 revenue growth of 20.1% year-over-year, leading to raised full-year guidance and a strategic acquisition to expand its cardiac monitoring capabilities. Despite being unprofitable, the company is considered 22.6% undervalued based on its GF Value™ and shows strong fundamentals with a GF Score™ of 79, driven by high growth and valuation ranks. However, mixed guru ownership and net insider selling indicate cautious optimism and suggest that IRTC remains a speculative growth stock.
